Anavex gets FDA meeting on pediatric Rett Phase 3

AVXL obtained FDA agreement for a meeting to discuss adding pediatric patients to its planned Phase 3 Rett syndrome trial of ANAVEX 2-73.

Rhea-AI Filing Summary

ANAVEX LIFE SCIENCES CORP. (AVXL) reports a regulatory development related to its ANAVEX®2-73 (blarcamesine) program in Rett syndrome. The company is advancing a Phase 3 clinical trial in adult Rett patients in the United States and has received U.S. Food and Drug Administration agreement to hold a meeting to discuss potential inclusion of pediatric patients in this Phase 3 study. Anavex states that ANAVEX 2-73 remains a priority in its clinical development pipeline for early Alzheimer’s disease, Rett syndrome and Fragile X syndrome.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Figures

Disclosure date: September 9, 2026 Trial designation: ANAVEX 2-73-RS-005 Development stages mentioned: Phase 3

3 metrics

Disclosure date September 9, 2026 Date Anavex reported the FDA granting a meeting on pediatric inclusion

Trial designation ANAVEX 2-73-RS-005 Identifier for the planned Phase 3 clinical trial in adult Rett syndrome patients

Development stages mentioned Phase 3 Stage of the planned clinical trial for ANAVEX 2-73 in Rett syndrome

Key Terms

Phase 3 clinical trial, Rett syndrome, Fragile X syndrome, pediatric patients, +1 more

5 terms

Phase 3 clinical trial medical

"the initiation of a Phase 3 clinical trial for ANAVEX 2-73 in Rett syndrome"

A phase 3 clinical trial is a large-scale study that tests a new medical treatment or drug to determine if it is safe and effective for widespread use. It often involves hundreds or thousands of participants and compares the new treatment to existing options or a placebo. For investors, the results of this phase are crucial, as successful outcomes can lead to regulatory approval and commercial success, while failures may halt development.

Rett syndrome medical

"Phase 3 clinical trial for ANAVEX 2-73 in Rett syndrome in adult patients"

A rare genetic disorder that disrupts normal brain development in young children, most commonly girls, leading to slowed growth, loss of purposeful hand use, repetitive hand movements, motor problems, speech loss, and cognitive and breathing irregularities. Investors watch it because its severity and few treatment options create clear medical need and potential markets for therapies; think of it as a broken traffic signal in the brain that, if fixed, could restore many downstream functions.

Fragile X syndrome medical

"clinical development pipeline in early Alzheimer’s disease, Rett syndrome and Fragile X syndrome"

Fragile X syndrome is a hereditary genetic disorder that typically causes intellectual disability, developmental delays, and behavioral and learning challenges; think of it as a missing or altered instruction in the body’s blueprint that affects brain development. It matters to investors because treatments, diagnostics, and supportive therapies for the condition represent potential markets and clinical trial opportunities; progress or setbacks in research, approvals, or reimbursement can materially affect companies working in related drugs, tests, or services.

pediatric patients medical

"meeting to discuss inclusion of pediatric patients in its Phase 3 clinical trial"

blarcamesine medical

"advancement of its ANAVEX 2-73 (blarcamesine) clinical development pipeline"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What regulatory update did ANAVEX (AVXL) announce regarding ANAVEX 2-73?

ANAVEX announced that the U.S. Food and Drug Administration has granted its request for a meeting to discuss inclusion of pediatric patients in the planned Phase 3 clinical trial of ANAVEX 2-73 in Rett syndrome.

Which indications is ANAVEX (AVXL) prioritizing for ANAVEX 2-73?

ANAVEX is prioritizing development of ANAVEX 2-73 (blarcamesine) in early Alzheimer’s disease, Rett syndrome and Fragile X syndrome in the United States, with a planned Phase 3 trial in adult Rett patients.

What is the focus of the upcoming Phase 3 trial mentioned by AVXL?

The upcoming Phase 3 trial, designated ANAVEX 2-73-RS-005, focuses on ANAVEX 2-73 in adult Rett syndrome patients, and Anavex plans to discuss with the FDA whether pediatric patients can be included in this study.

Did ANAVEX (AVXL) receive FDA approval for ANAVEX 2-73 in this filing?

No. The company reported that the FDA granted a meeting to discuss including pediatric patients in its Phase 3 Rett syndrome trial. The disclosure does not state any marketing approval for ANAVEX 2-73.

When did ANAVEX disclose the FDA meeting regarding pediatric inclusion?

ANAVEX disclosed on September 9, 2026 that the U.S. Food and Drug Administration had granted its request for a meeting to discuss inclusion of pediatric patients in its Phase 3 Rett syndrome trial with ANAVEX 2-73.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/09/2026 - 05:18 PM EDT Accepted by SEC EDGAR 09/09/2026 - 05:17 PM EDT Learn about SEC filing dates

false 0001314052 0001314052 2026-09-09 2026-09-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 9, 2026

ANAVEX LIFE SCIENCES CORP. 

(Exact name of Registrant as Specified in Its Charter)

Nevada	001-37606	98-0608404
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
630 5th Avenue, 20th Floor New York, NY USA		10111
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: 1-844-689-3939

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		AVXL		Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

As previously disclosed, Anavex Life Sciences Corp. (“Anavex” or the “Company”) is prioritizing the advancement of its ANAVEX®2-73 (blarcamesine) clinical development pipeline in early Alzheimer’s disease, Rett syndrome and Fragile X syndrome in the United States, and the Company is moving forward with the initiation of a Phase 3 clinical trial for ANAVEX 2-73 in Rett syndrome in adult patients (ANAVEX 2-73-RS-005).

On September 9, 2026, the Company disclosed that the U.S. Food and Drug Administration has granted the Company’s request for a meeting to discuss inclusion of pediatric patients in its Phase 3 clinical trial for ANAVEX 2-73 in Rett syndrome.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ANAVEX LIFE SCIENCES CORP.
Date: September 9, 2026	By:	/s/ Sandra Boenisch
		Sandra Boenisch, CPA, CGA Principal Financial Officer, Treasurer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 2.9 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB